Author

D. R. Spitz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:cancer & tumor microenvironment· 3 Organism:human· 3 Organism:mouse· 3 Assay:metabolomics· 2 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

B. G. Allen· 2 shared A. H. Mahalingam· 1 shared A. M. Bellizzi· 1 shared A. Mauguen· 1 shared A. Meyer· 1 shared A. R. Jackson· 1 shared A. Rauckhorst· 1 shared A. Sadanandam· 1 shared

Activity by Year

2021-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 10 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. G. Allen

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Auranofin Inhibition of Thioredoxin Reductase Sensitizes Lung Neuroendocrine Tumor Cells (NETs) and Small Cell Lung Cancer (SCLC) Cells to Sorafenib as well as Inhibiting SCLC Xenograft Growth

S. S. Johnson, D. Liu, J. T. Ewald, C. Robles-Planells, K. A. Christiansen, K. Bayanbold, B. R. Wels, S. R. Solst, M. S. ODorisio, B. G. Allen, Y. Menda, D. R. Spitz, M. Fath

This study shows auranofin inhibits TrxR in SCLC and NET cells, sensitizes them to sorafenib, and extends survival in xenograft models without toxicity.

bioRxiv · May 7, 2023Cancer Biology

Inhibition of serotonin biosynthesis in neuroendocrine neoplasm suppressestumor growth in vivo

D. H. Tow, C. G. Tran, L. C. Borbon, M. Ridder, G. Li, C. A. Kaemmer, E. Abusada, A. H. Mahalingam, A. Sadanandam, C. Chandrasekharan, J. Dillon, D. R. Spitz, D. E. Quelle, C. H. F. Chan, A. M. Bellizzi, , P. H. Ear

This study shows that inhibiting serotonin biosynthesis in neuroendocrine neoplasms reduces tumor growth in vivo but not in vitro.

bioRxiv · Apr 7, 2023 · PreprintCancer Biology

Tubular Mitochondrial Pyruvate Carrier Disruption Elicits Redox Adaptations that Protect from Acute Kidney Injury

A. Rauckhorst, G. V. Martinez, G. M. Andrade, H. Wen, J. Y. Kim, A. Simoni, K. A. Mapuskar, P. Rastogi, E. J. Steinbach, M. L. McCormick, B. G. Allen, A. R. Jackson, N. S. Pabla, M. C. Coleman, D. R. Spitz, , D. Zepeda-Orozco

The paper shows that reducing mitochondrial pyruvate carrier activity in kidney tubular cells protects against acute kidney injury by enhancing redox defenses and survival.

bioRxiv · Jan 31, 2023Biochemistry

H3.1Cys96 oxidation by mitochondrial ROS promotes chromatin remodeling, breast cancer progression to metastasis and multi-drug resistance

F. R. Palma, F. T. Ogata, D. R. Coelho, K. Pulakanti, A. Meyer, Y. Huang, J. M. Daves, M. J. Schipma, C. M. Furdui, D. R. Spitz, B. N. Gantner, S. Rao, V. Backman, M. G. Bonini

The paper shows that mitochondrial H2O2 oxidizes H3.1 at Cys96, promoting chromatin remodeling, breast cancer metastasis, and drug resistance.

bioRxiv · Dec 1, 2022 · PreprintCancer Biology

Sex Differences in Brain Tumor Glutamine Metabolism Reveal Sex-Specific Vulnerabilities to Treatment

J. Sponagel, J. K. Jones, C. Frankfater, S. Zhang, O. Tung, K. Cho, K. L. Tinkum, H. Gass, E. Nunez, D. R. Spitz, P. Chinnaiyan, J. Schaefer, G. J. Patti, M. S. Graham, A. Mauguen, , J. E. Ippolito

The paper identifies sex differences in glutamine metabolism in glioblastomas, showing male tumors have higher glutamine uptake and are more sensitive to GLS1 inhibition than female tumors.

bioRxiv · Sep 29, 2021Cancer Biology